CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-04 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −120 | $242.70 | $29K | 24,542 |
| 2025-03-03 | Hesslein Robert W. EVP, CLO and Secretary | Grant or award | +757 | 8,002 | ||
| 2025-03-03 | Hesslein Robert W. EVP, CLO and Secretary | Grant or award · Stock Option (right to buy) | +1,529 | 1,529 | ||
| 2025-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Grant or award 10b5-1 | +3,871 | 16,256 | ||
| 2025-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −204 | $242.37 | $49K | 16,052 |
| 2025-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −224 | $243.36 | $55K | 15,828 |
| 2025-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −151 | $244.41 | $37K | 15,677 |
| 2025-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −111 | $245.26 | $27K | 15,566 |
| 2025-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −45 | $246.18 | $11K | 15,521 |
| 2025-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −4 | $247.35 | $989 | 15,517 |
| 2025-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −1 | $248.36 | $248 | 15,516 |
| 2025-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −465 | $242.69 | $113K | 15,051 |
| 2025-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −487 | $243.94 | $119K | 14,564 |
| 2025-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −219 | $245.30 | $54K | 14,345 |
| 2025-03-03 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Grant or award · Stock Option (right to buy) 10b5-1 | +7,819 | 7,819 | ||
| 2025-03-03 | Tanguler Tolga EVP, Chief Commercial Officer | Grant or award | +14,137 | 28,482 | ||
| 2025-03-03 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −131 | $242.37 | $32K | 28,351 |
| 2025-03-03 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −142 | $243.36 | $35K | 28,209 |
| 2025-03-03 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −96 | $244.41 | $23K | 28,113 |
| 2025-03-03 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −70 | $245.26 | $17K | 28,043 |
Page 31 of 41 · 816 trades